Roozbeh Jamshid, Eshraghian Ahad, Raeesjalali Ghanbarali, Behzadi Saeed, Nikeghbalian Saman, Sagheb Mohammad Mehdi, Salehipour Mehdi, Bahador Ali, Salahi Heshmatollah, Malekhosseini Seyed Ali
Shiraz Organ Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Iran.
Iran J Kidney Dis. 2011 Jan;5(1):53-6.
INTRODUCTION. This study aimed to compare outcomes of kidney transplantation in patients with systemic lupus erythematosus (SLE) and a matched control group of non-SLE kidney recipients. MATERIALS AND METHODS. In a case-control study, 33 patients with kidney transplantation due to end-stage renal disease caused by SLE were matched to a control group consisted of 33 non-SLE patients who had been transplanted during the same period of time in our center. The clinical characteristics, complications, and patient and graft survival were compared between the two groups. RESULTS. In each group, 12 patients (36.4%) received a kidney from a deceased donor, 15 (45.4%) from a living unrelated donor, and 6 (18.2%) from a living related donor. There was no significant difference between the outcome in SLE patients and duration of dialysis before transplantation. The mean duration of hospital stay was 23.4 ± 18.1 days in the SLE group, while it was 13.0 ± 7.3 days in the controls (P = .006). One-year graft survival was 79.0% in patients with SLE and 90.9% in non-SLE patients (P = .17). One-year patient survival was 93.9% in patients with SLE versus 81.8% in the controls (P = .26). Nine patients in the SLE group versus 11 patients in the control group developed posttransplant complications (P = .59). CONCLUSIONS. Although hospital stay after transplantation was longer in the SLE kidney recipients than controls, safety of kidney transplantation was comparable. Graft failure in the SLE patients was not significantly different between patients with different sources of kidneys.
引言。本研究旨在比较系统性红斑狼疮（SLE）患者与匹配的非SLE肾移植受者对照组的肾移植结局。材料与方法。在一项病例对照研究中，33例因SLE导致终末期肾病而接受肾移植的患者与由33例同期在本中心接受移植的非SLE患者组成的对照组进行匹配。比较两组的临床特征、并发症以及患者和移植物的存活率。结果。每组中，12例患者（36.4%）接受了来自 deceased donor的肾脏，15例（45.4%）来自 living unrelated donor，6例（18.2%）来自 living related donor。SLE患者的结局与移植前透析时间之间无显著差异。SLE组的平均住院时间为23.4±18.1天，而对照组为13.0±7.3天（P = 0.006）。SLE患者的1年移植物存活率为79.0%，非SLE患者为90.9%（P = 0.17）。SLE患者的1年患者存活率为93.9%，对照组为81.8%（P = 0.26）。SLE组9例患者与对照组11例患者发生移植后并发症（P = 0.59）。结论。尽管SLE肾移植受者移植后的住院时间比对照组长，但肾移植的安全性相当。不同肾脏来源的SLE患者的移植物失败率无显著差异。
